This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About

About

Efficacy
MOAMist MomentsSafety & Dosing

Safety &
Dosing

SafetyDosing & AdministrationFormulary CoverageSavings & Support

Savings
& Support

Savings & Support OptionsPrior Authorization ResourcesMaterialsVideo
Prescribing InformationPatient Information Instructions for UseIndication Press Release
MOAThe ONLY CGRP receptor antagonist nasal spray1,2

ZAVZPRET is rapidly absorbed in the nasal cavity, directly entering the bloodstream, avoiding GI absorption and first-pass metabolism.1,3

Peak plasma concentration of zavegepant was observed at approximately 30 minutes after a single 10 mg dose of the nasal spray.1 In the video below, learn more about migraine pathophysiology and how ZAVZPRET works.

MOA=mechanism of action

MOA=mechanism of action

About
Learn more about how to administer ZAVZPRET
 Watch now Loading
Connect with a sales representative to learn more
 Request a representative Loading
Could ZAVZPRET be right for your patients?

Ben is a teacher with migraine who often endures the pain while teaching.

 Ben’s Mist Moment LoadingReferences:Zavzpret. Package insert. Pfizer Inc.Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(13):209-217. doi:10.1016/S1474-4422(22)00517-8Bitter C, Sutter-Zimmerman K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40:20-35. doi:10.1159/000321044Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success. J Med Chem. 2020;63(13):6600-6623. doi:10.1021/acs.jmedchem.9b01810Favoni V, Giana L, Al-Hassany L et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20(1):27.doi:10.1186.1186/s10194-019-0979-yDurham PL. CGRP-receptor antagonists — a fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073-1075. doi: 10.1056/NEJMp048016

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-ZAZ-USA-0878
You are now leaving PfizerPro

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367

INDICATION

ZAVZPRET® (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety InformationContraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, facial swelling, and urticaria, have occurred in patients treated with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists.

If signs or symptoms of Raynaud’s phenomenon develop, discontinue ZAVZPRET. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. 

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs <1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.
 
Use in Specific Populations: Pregnancy: It is not known if ZAVZPRET can harm an unborn baby. Lactation: It is not known whether ZAVZPRET passes into breast milk. Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.
IndicationZAVZPRET (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please click here for full
Prescribing Information.